Qishen Granule Protects against Doxorubicin‐Induced Cardiotoxicity by Coordinating MDM2‐p53‐Mediated Mitophagy and Mitochondrial Biogenesis
Open Access
- 6 September 2022
- journal article
- research article
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2022 (1) , 4344677
Abstract
Doxorubicin (DOX), the anthracycline chemotherapeutic agent, is widely used for the treatment of various cancers. However, its clinical application is compromised by dose‐dependent and fatal cardiotoxicity. This study is aimed at investigating the cardioprotective effects of Qishen granule (QSG) and the specific mechanism by which QSG alleviates DOX‐induced cardiotoxicity (DIC) and providing an alternative for the treatment of DIC. We first evaluated the cardioprotective effects of QSG in a DIC mouse model, and the obtained results showed that QSG significantly protected against DOX‐induced myocardial structural and functional damage, mitochondrial oxidative damage, and apoptosis. Subsequently, after a comprehensive understanding of the specific roles and recent developments of p53‐mediated mitochondrial quality control mechanisms in DIC, we investigated whether QSG acted on MDM2 to regulate the activity of p53 and downstream mitophagy and mitochondrial biogenesis. The in vivo results showed that DOX inhibited mitochondrial biogenesis and blocked mitophagy in the mouse myocardium, while QSG reversed these effects. Mechanistically, we combined nutlin‐3, which inhibits the binding of p53 and MDM2, with DOX and QSG and evaluated their influence on mitophagy and mitochondrial biogenesis in H9C2 cardiomyocytes. The obtained results showed that both DOX and nutlin‐3 substantially inhibited mitophagy and mitochondrial biogenesis and induced mitochondrial oxidative damage and apoptosis, which could be partially recovered by QSG. Importantly, the immunoprecipitation results showed that QSG promoted the binding of MDM2 to p53, thus decreasing the level of p53 protein and the binding of p53 to Parkin. Collectively, QSG could promote the degradation of p53 by enhancing the binding of MDM2 to the p53 protein, resulting in the reduced binding of p53 to the Parkin protein, thus improving Parkin‐mediated mitophagy. Increased degradation of p53 protein by QSG simultaneously enhanced mitochondrial biogenesis mediated by PGC‐1α. Ultimately, QSG relieved DOX‐induced mitochondrial oxidative damage and apoptosis by coordinating mitophagy and mitochondrial biogenesis.Keywords
Funding Information
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China (82174364, 81904169, 81822049)
This publication has 45 references indexed in Scilit:
- Identification of the molecular basis of doxorubicin-induced cardiotoxicityNature Medicine, 2012
- Telomere dysfunction induces metabolic and mitochondrial compromiseNature, 2011
- Dexrazoxane (Totect™): FDA Review and Approval for the Treatment of Accidental Extravasation Following Intravenous Anthracycline ChemotherapyThe Oncologist, 2008
- Transcriptional Paradigms in Mammalian Mitochondrial Biogenesis and FunctionPhysiological Reviews, 2008
- Dexrazoxane-Associated Risk for Acute Myeloid Leukemia/Myelodysplastic Syndrome and Other Secondary Malignancies in Pediatric Hodgkin's DiseaseJournal of Clinical Oncology, 2007
- Regulation of p53 stability by Mdm2Nature, 1997
- Mdm2 promotes the rapid degradation of p53Nature, 1997
- Anthrazykline in der KrebstherapieDrugs, 1997
- Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53Nature, 1993
- The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivationCell, 1992